相关实验视频

Updated: Jan 16, 2026

A Melanoma Patient-Derived Xenograft Model

A Melanoma Patient-Derived Xenograft Model

Published on: May 20, 2019

新的非洲-加勒比前列腺癌模型揭示了祖先特定的药物脆弱性,对黑人患者有治疗意义

Simone Badal^1,2, Bor-Jang Hwang³, Ashlianne Nelson^1,2

¹Department of Basic Medical Sciences, Faculty of Medical Sciences Teaching and Research Complex, The University of the West Indies, Mona, Jamaica.

Cancer research communications

|October 2, 2025

概括

一个新的非洲-加勒比前列腺癌细胞系,ACRJ-PC28,揭示了依赖于祖先的药物反应. 这凸显了需要多样化的模型来改善针对黑人患者的前列腺癌向治疗方法.

科学领域:

在瘤学瘤学.
遗传学是一个遗传学.
药理学药理学是指药理学的学科.

背景情况:

前列腺癌不成比例地影响黑人人口,在临床前模型中代表性有限.
现有的模型不足以捕捉对理解差异性药物反应至关重要的遗传多样性.

研究的目的:

介绍ACRJ-PC28,一种新的非洲-加勒比前列腺癌细胞系.
评估对主要前列腺癌治疗方法的祖先依赖药物敏感性.
为代表性不足的患者群体制定个性化治疗策略.

主要方法:

建立并描述了ACRJ-PC28细胞系.
在多个细胞系中使用三个不同的测试 (ACRJ-PC28,MDA-PCA-2b,DU-145,PC-3) 评估药物活力.
进行RNA测序以确定药物反应的遗传相关物.

主要成果:

ACRJ-PC28对阿比拉具有独特的敏感性 (IC50 = 1.10 μmol/L),明显高于其他细胞系.
与白人捐赠者相比,黑人捐赠者的细胞系中恩扎胺的疗效降低了 (3-5倍的差异).
TNF家族基因的表达不足,特别是TNFRSF14,与黑色供体细胞系的差异性药物反应相关.

结论:

新的ACRJ-PC28细胞系为研究非洲-加勒比人口的前列腺癌提供了有价值的模型.
祖先特定的药物敏感性强调了当前临床前模型的局限性.
结合多样化的细胞系对于开发前列腺癌的精准医学方法至关重要.

更多相关视频

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms

Published on: December 9, 2015

Establishment of Zebrafish Patient-Derived Xenografts from Pancreatic Cancer for Chemosensitivity Testing

Establishment of Zebrafish Patient-Derived Xenografts from Pancreatic Cancer for Chemosensitivity Testing

Published on: May 12, 2023

相关概念视频

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...